Filippo Spriano

This study identifies IL-16 production as a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas, showing that targeting the IL-16/CD9 axis restores drug sensitivity.

This study identifies multiple resistance mechanisms to ETS-targeting agents in DLBCL and suggests combination therapies with BCL2, MCL1, and XPO1 inhibitors.

This study evaluates the antitumor activity of seven natural antimicrobial peptides against MZL cell lines and resistant derivatives, finding W-trematocine and temporin L show potent cytotoxicity with low toxicity to non-malignant cells.

The paper characterizes ROR1 expression in B-cell lymphoma models and shows that ROR1-positive models are sensitive to a ROR1-targeting ADC.

This study identifies PLK1 inhibition as a strategy to enhance BTK blockade in MZL by overcoming resistance through transcriptomic and mechanistic analysis.

This paper evaluates the effectiveness of 177Lu-lilotomab satetraxetan in lymphoma cell lines, showing it is more effective in CD37-positive B-cell lymphomas and identifies potential biomarkers and synergistic combinations.

This study shows that combining CXCR4 inhibitors with standard and targeted therapies improves anti-tumor effects in B-cell lymphoma models, especially in drug-resistant cases.

This study evaluates KAT/3BP, a 3BP derivative, showing in vitro and in vivo anti-tumor activity against lymphoma models, including resistant cell lines and synergistic effects with existing therapies.

This paper develops a 3D co-culture system using bone marrow stromal cells to study drug resistance in B cell non-Hodgkin lymphoma and identifies potential resistance mediators.

This paper identifies ADARreg, an elncRNA that modulates BCR signaling and immune evasion in lymphoma by altering RNA stability, localization, and editing, providing a potential therapeutic target.